[ Editor’s Note: Yes, this is the lowest effectiveness vaccine in terms of those who can still get Covid, but the good part is that it prevented hospitalizations and deaths, which is the big concern.
The same was true of the Pfizer vaccine. After vaccination, people still could get Covid, but I read two days ago that no one had been hospitalized or died after being vaccinated, an important benefit.
Also, the new Johnson & Johnson vaccine is more suitable for use in rural areas, easier to ship, and it’s a ‘one shot and you are done’ deal. Not having a one size fits all approach is turning out to be a benefit, as planners can match vaccines to the needs of the public.
Since the Covid variants are spreading quickly now, the name of the game is to get as many people vaccinated as possible to avoid the worst case statistics of severe illness, so we can kill Covid this summer, which will set the stage for a sustained recovery in the autumn, with much needed improvement in employment figures.
Sure, a lot of Trumpers are anti-vax people, but they have been dedicated spreaders, and I question their logic. If these people had been paid by a strategic US adversary to spread Covid, it would be capital crime, but their doing it on their own free will seems to be a freebie… Jim W. Dean ]
First published … February 27, 2021
A Food and Drug Administration advisory committee endorsed Johnson & Johnson’s coronavirus vaccine on Friday, with panel members framing the shot as a crucial third option to vaccinate millions of Americans.
The vote clears the way for the agency to authorize the vaccine’s use in the coming days. The FDA “will rapidly work toward finalization and issuance of an emergency use authorization,” its top vaccine regulator, Peter Marks, and acting commissioner, Janet Woodcock, said in a statement shortly after the vote.
“The agency has also notified our federal partners involved in vaccine allocation and distribution so they can execute their plans for timely vaccine distribution.”
…“We need vaccines that are effective and well-tolerated. And importantly, ones that are simple to deploy,” said Gregory Poland, director of the Mayo Clinic’s vaccine research group, who spoke at the meeting as part of J&J’s presentation.
…“It’s all about the fear of getting really sick and getting sick enough potentially to seek medical attention, and to the point where one might need to go to the hospital or even die,” said Mathai Mammen, Janssen’s global research and development head, on an investor call in January. “Success against severe illness is by far the most important feature from a public health standpoint.”
Jim W. Dean Archives 2009-2014